A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
← catalyst calendarNCT07735637 · readout in 784 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
750estimated
Sites
65
Countries
Australia, Brazil, Canada +12
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-25 | estimated | When the study began enrolling |
| Primary completion | 2028-10-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2039-11-09 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Newly Diagnosed Multiple Myeloma (NDMM)
Interventions
- Biological: AZD0120
- Drug: Cyclophosphamide
- Drug: Fludarabine
- Drug: Melphalan (part of ASCT)
- Drug: Lenalidomide
Primary outcomes
what the primary-completion date above is the date OFProgression-Free Survival (PFS)
measured Up to approximately 13 years.
Minimal Residual Disease (MRD) negative Complete Response Rate (CRR)
measured Up to approximately 13 years.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed